Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac in Cataract Surgery
NCT00703781Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jun 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular inflammation and post-operative ocular pain comparing Bromfenac with Placebo (2 arms). Primary endpoint: Summed Ocular Inflammation Score of Zero at 15 days. Started Jun 2008; status: completed.
02
Drugs
bromfenac sodium
03
Conditions
ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT00703781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703781.